Clinical trials for lung cancer
130 currently recruiting clinical trials
If you are a doctor and would like find matching clinical trials for you patients, create an account or log in
If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial
Phase 2
Lung cancer
#NCT04956640
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
KRAS G12C
IUCT Oncopôle (Toulouse), Institut du cancer de Montpellier (Montpellier), Centre Léon Bérard (Lyon), Gustave Roussy (Villejuif), Institut Bergonié (Bordeaux)
Eli Lilly et compagnie
Phase 2
Lung cancer
#NCT05512377
NSCLC (Non-Small Cell Lung Cancer)
Metastatic
Other mutation
Systemic Treatment-Naive
Gustave Roussy (Villejuif), Institut Bergonié (Bordeaux), Hôpital Beaujon (Clichy), CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon )
Boehringer Ingelheim
Phase 2
Lung cancer
#NCT05882734
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
Immunotherapy
Chemotherapy
EGFR
ALK
Systemic Treatment-Naive
Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain), Centre Hospitalier Universitaire Dupuytren (Limoges), Centre Hospitalier Intercommunal Créteil (Créteil Cedex), CHU - Haut-lévêque - Bordeaux (Pessac), Centre Hospitalier Universitaire de Montpellier - Site Arnaud de Villeneuve (Montpellier) (and 2 more...)
Merck KGaA
Phase 2
Lung cancer
#NCT03915678
NSCLC (Non-Small Cell Lung Cancer)
Metastatic
Immunotherapy
Systemic Treatment-Naive
Institut Bergonié (Bordeaux), Centre Hospitalier Régional Et Universitaire CHRU de Brest (Brest), Centre François Baclesse (Caen ), CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Centre Oscar Lambret (Lille) (and 4 more...)
Institut Bergonié
Phase 2
Lung cancer
#NCT06099782
NSCLC (Non-Small Cell Lung Cancer)
Metastatic
Systemic Treatment-Naive
PDL1 Positive (>= 50%)
Immunotherapy
Immunotherapy
Bispecific T-cell engager antibodies
Centre Léon Bérard (Lyon), CHU Caen Normandie (Caen), Clinique Chénieux (Limoges), Hôpital Bichat - Claude Bernard - AP-HP (Paris), Hôpital d'Instruction des Armées Sainte-Anne (Toulon)
Merck Sharp & Dohme LLC
Phase 2
Lung cancer
#NCT05967689
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
Systemic Treatment-Naive
Immunotherapy
Chemotherapy
Targeted therapy
Systemic Treatment-Naive
Centre Hospitalier Universitaire de Strasbourg - Nouvel Hopital Civil (Strasbourg), CHU Caen Normandie (Caen), Institut Curie - Paris (Paris), Centre Hospitalier Universitaire Dupuytren (Limoges), Centre Hospitalier Universitaire Laennec (Saint-Herblain) (and 4 more...)
Taiho Oncology
Phase 2
Lung cancer
#NCT05925530
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Systemic Treatment-Naive
EGFR
ALK
Immunotherapy
Chemotherapy
Targeted therapy
Car-T
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Centre Hospitalier Universitaire de Grenoble (La Tronche), Hôpital de la Timone AP-HM (Marseille), Institut Curie - Paris (Paris), Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers), Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier) (and 1 more...)
AstraZeneca
Phase 2
Lung cancer
#NCT05882058
SCLC (Small Cell Lung Cancer)
Locally Advanced
Metastatic
Immunotherapy
Chemotherapy
Systemic Treatment-Naive
Car-T
Bispecific T-cell engager antibodies
Hôpital Cochin (Paris ), Centre Hospitalier Intercommunal Créteil (Créteil Cedex), Centre Hospitalier Universitaire de Strasbourg - Nouvel Hopital Civil (Strasbourg)
Boehringer Ingelheim
Phase 2
Lung cancer
#NCT05688280
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
Immunotherapy
Chemotherapy
Systemic Treatment-Naive
Institut Bergonié (Bordeaux), Hôpital Pitié Salpêtrière - AP-HP (Paris), Hôpital Foch (Suresnes)
Immunophotonics
Phase 2
Lung cancer
#NCT05609578
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
KRAS G12C
Systemic Treatment-Naive
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
Targeted therapy
Immunotherapy
Chemotherapy
Targeted therapy
Car-T
Bispecific T-cell engager antibodies
Hôpital Larrey (Toulouse ), Centre Hospitalier Intercommunal Créteil (Créteil Cedex), Hôpital Tenon AP-HP (Paris ), CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Centre François Baclesse (Caen ) (and 5 more...)
Mirati Thérapeutique Inc.